Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EBIT (2016 - 2025)

Historic EBIT for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$3.2 million.

  • Anika Therapeutics' EBIT fell 389135.8% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.4 million, marking a year-over-year decrease of 16107.55%. This contributed to the annual value of -$5.1 million for FY2024, which is 70438.39% down from last year.
  • Anika Therapeutics' EBIT amounted to -$3.2 million in Q3 2025, which was down 389135.8% from -$4.2 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' EBIT registered a high of $24.7 million during Q4 2023, and its lowest value of -$12.6 million during Q1 2023.
  • In the last 5 years, Anika Therapeutics' EBIT had a median value of -$3.2 million in 2025 and averaged -$508894.7.
  • In the last 5 years, Anika Therapeutics' EBIT skyrocketed by 27979.83% in 2022 and then crashed by 389135.8% in 2025.
  • Quarter analysis of 5 years shows Anika Therapeutics' EBIT stood at -$9.1 million in 2021, then skyrocketed by 279.8% to $16.4 million in 2022, then surged by 50.59% to $24.7 million in 2023, then crashed by 102.85% to -$705000.0 in 2024, then tumbled by 358.58% to -$3.2 million in 2025.
  • Its EBIT stands at -$3.2 million for Q3 2025, versus -$4.2 million for Q2 2025 and -$4.3 million for Q1 2025.